Latest News

Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD

March 18th 2024

The gene-edited cell therapy has been approved as Lenmeldy by the FDA.

FDA Approves Orchard Therapeutics’ Gene-Edited Cell Therapy Arsa-Cel for Metachromatic Leukodystrophy
FDA Approves Orchard Therapeutics’ Gene-Edited Cell Therapy Arsa-Cel for Metachromatic Leukodystrophy

March 18th 2024

First Patient Treated in Trial for NSCLC T-cell Therapy Deltacel Shows Evidence of Tumor Reduction
First Patient Treated in Trial for NSCLC T-cell Therapy Deltacel Shows Evidence of Tumor Reduction

March 18th 2024

Michael Kelly, PhD
Michael Kelly, PhD, on Gene Therapy’s Continuing Path to Treating DMD

March 18th 2024

If CAR-T Proves Able to Effectively and Durably Treat Autoimmune Disease it May Greatly Benefit Lives of Patients
If CAR-T Proves Able to Effectively and Durably Treat Autoimmune Disease it May Greatly Benefit Lives of Patients

March 17th 2024

Video Interviews

Conference Coverage

View All
If CAR-T Proves Able to Effectively and Durably Treat Autoimmune Disease it May Greatly Benefit Lives of Patients
If CAR-T Proves Able to Effectively and Durably Treat Autoimmune Disease it May Greatly Benefit Lives of Patients

March 17th 2024

Sandra P. Reyna, MD, the chief scientific advisor and head of global medical engagement for SMA at Novartis
Evaluating Spinal Muscular Atrophy Gene Therapy Zolgensma in Heavier and Older Patients

March 16th 2024

Alan Beggs, PhD
Alan Beggs, PhD, on Lessons Learned With Developing X-Linked Myotubular Myopathy Gene Therapy

March 15th 2024

John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine
John Ligon, MD, on Establishing a Roadmap for CAR-T Fertility Research

March 14th 2024

All News

© 2024 MJH Life Sciences

All rights reserved.